Tenderwize
Zurück zur Suche

Open-house rebate agreement for Leuprorelin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Leuprorelin, ATC L02AE02

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Submitting through the wrong portal area is explicitly prohibited; the notice says contract documents must be submitted...

The monthly cut-off is strict: complete and correct documents must be received by the 3rd for the next month’s start, a...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive open-house rebate agreements for Leuprorelin, ATC L02AE02.
  • Supply of pharmaceutical products under identical, non-individually negotiated contract terms.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical rebate agreements on Leuprorelin (ATC L02AE02) in Germany, led by AOK Bayern. The notice states that this is not a competitive procurement: all pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. No contract value is stated. Submission is via DTVP or by paper originals, with monthly cut-off rules for contract start dates.

Risiken

Submitting through the wrong portal area is explicitly prohibited; the notice says contract documents must be submitted...

The monthly cut-off is strict: complete and correct documents must be received by the 3rd for the next month’s start, a...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only pharmaceutical companies may participate as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Leuprorelin

Open-house non-exclusive rebate agreement for the pharmaceutical product Leuprorelin (ATC L02AE02). Scope is supplies of pharmaceutical products. The lot information comes from structured data and the XML notice. Performance is in Germany, region DE212 (Bavaria/Munich area as buyer location, but place of performance is only given at country/subdivision level).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Sep 2025 - Sep 2027

Kategorie

Pharmaceutical products

Frist

Deadline Aug 03, 2027

Vergabedetails

Veröffentlichungsdatum
13 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
533423-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30